Non Hodgkin Lymphoma Clinical Trial

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Summary

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

View Full Description

Full Description

This is a non-therapeutic study design. After successful screening, subjects will be monitored for potential gene therapy-related adverse events for up to 15 years post MB-CART2019.1 infusion. Subjects will be assessed yearly for the occurrence of delayed adverse events (AEs), monitored for replication competent lentivirus (RCL) and assessed for long term efficacy as well as CAR-T persistence.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
Provided written informed consent to participate in this study.

Exclusion Criteria:

None

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

150

Study ID:

NCT06116110

Recruitment Status:

Not yet recruiting

Sponsor:

Miltenyi Biomedicine GmbH

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Stanford University
Stanford California, 94305, United States More Info
Sharan Claire
Contact
[email protected]
Yale University
New Haven Connecticut, 06520, United States More Info
Jialing Zhang
Contact
[email protected]
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore Maryland, 21201, United States More Info
Nancy Hardy, MD
Contact
[email protected]
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Christopher Simmons
Contact
[email protected]
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Rosin McAndrew
Contact
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

150

Study ID:

NCT06116110

Recruitment Status:

Not yet recruiting

Sponsor:


Miltenyi Biomedicine GmbH

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.